Adaptive Biotechnologies
ADPT
209 hedge funds and large institutions have $1.08B invested in Adaptive Biotechnologies in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 89 increasing their positions, 58 reducing their positions, and 40 closing their positions.
289% more call options, than puts
Call options by funds: $1.62M | Put options by funds: $417K
53% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 58
5.6% more ownership
Funds ownership: 88.77% → 94.37% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 222 → 209 (-13)
28% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 40
38% less capital invested
Capital invested by funds: $1.74B → $1.08B (-$660M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$27.4M |
| 2 |
BlackRock
New York
|
+$26.9M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$9.35M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.4M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$17.9M |
| 2 |
CC
Casdin Capital
New York
|
-$13.9M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$10.9M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$9M |
| 5 |
TM
Tiger Management
New York
|
-$8.18M |
ADPT Hedge Fund Activity: Q2 2022 in Review
209 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q2 2022, worth a combined $1.08B — down 38% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of ADPT and 29 opened new positions — a net loss of 11 holders — while 58 trimmed existing stakes and 89 added.
The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $27.4M. The largest seller was Massachusetts Financial Services, cutting an estimated $17.9M.
- 209 institutional investors held Adaptive Biotechnologies (ADPT) as of Q2 2022, down from 222 in Q1 2022.
- Funds reported $1.08B of Adaptive Biotechnologies stock for Q2 2022, down 38% quarter-over-quarter.
- 29 funds opened new Adaptive Biotechnologies positions in Q2 2022 and 40 closed out, a net change of -11 holders.
- The largest Adaptive Biotechnologies buyer in Q2 2022 was Blue Water Life Science Advisors, an estimated $27.4M added.
- The largest Adaptive Biotechnologies seller in Q2 2022 was Massachusetts Financial Services, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2022.